Keyphrases
Bevacizumab
100%
Phase II Study
100%
Recurrent Glioblastoma multiforme
100%
Combination Therapy
100%
Glioblastoma multiforme
50%
Overall Survival
25%
Median Progression-free Survival
25%
Phosphoinositide 3-kinase (PI3K)
12%
Phosphatase
12%
Radiological Response
12%
Chemoradiotherapy
12%
Chemotherapy
12%
Second-line Therapy
12%
MTOR Inhibitor
12%
Overall Safety
12%
Unfavorable Prognosis
12%
Hypertriglyceridemia
12%
Protein Kinase B/Akt
12%
High Activity
12%
Therapeutic Benefits
12%
Two-stage Design
12%
Thrombocytopenia
12%
Open Phase
12%
Hyperglycemia
12%
Hypercholesterolemia
12%
High-grade Glioma
12%
Blood Samples
12%
Temozolomide
12%
Adult Patients
12%
Monotherapy
12%
Partial Remission
12%
Hypertension
12%
Tensin Homolog
12%
Stable Disease
12%
Mammalian Target of Rapamycin (mTOR)
12%
Serious Adverse Events
12%
Vascular Endothelial Growth Factor
12%
Kinase Protein
12%
Pharmacology, Toxicology and Pharmaceutical Science
Glioblastoma
100%
Combination Therapy
100%
Bevacizumab
100%
Side Effect
33%
Progression Free Survival
22%
Overall Survival
22%
Vasculotropin
11%
Thrombocytopenia
11%
Glioma
11%
Phosphatase
11%
Chemoradiation Therapy
11%
Diseases
11%
Infection
11%
Tensin
11%
Adverse Event
11%
Temozolomide
11%
Mammalian Target of Rapamycin Inhibitor
11%
Protein Kinase B
11%
Remission
11%
Recurrent Disease
11%
Monotherapy
11%
Biological Marker
11%
Hypertriglyceridemia
11%
Hyperglycemia
11%
Mammalian Target of Rapamycin
11%
Hypercholesterolemia
11%
Chemotherapy
11%
Phosphatidylinositide
11%